{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:26:40Z","timestamp":1793986000628,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41409-026-03003-y","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:42:22Z","timestamp":1787661742000},"page":"1526-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and risk factors of Epstein-Barr virus infection and post-transplant lymphoproliferative disorder in paediatric haploidentical allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1770-4920","authenticated-orcid":false,"given":"Xin Yee","family":"Chiew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Hua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Xi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-2231","authenticated-orcid":false,"given":"Yu-Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7945","authenticated-orcid":false,"given":"Xiao-dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-7465","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-1081","authenticated-orcid":false,"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-256X","authenticated-orcid":false,"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-9034","authenticated-orcid":false,"given":"Yi-Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"3003_CR1","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185:3652\u201370.","journal-title":"Cell"},{"key":"3003_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jmv.24989","volume":"90","author":"L Wen","year":"2018","unstructured":"Wen L, Qiu Y, Cheng S, Jiang X, Ma YP, Fang W, et al. Serologic and viral genome prevalence of HSV, EBV, and HCMV among healthy adults in Wuhan, China. J Med Virol. 2018;90:571\u201381.","journal-title":"J Med Virol"},{"key":"3003_CR3","doi-asserted-by":"publisher","first-page":"e99857","DOI":"10.1371\/journal.pone.0099857","volume":"9","author":"G Xiong","year":"2014","unstructured":"Xiong G, Zhang B, Huang M-y, Zhou H, Chen L-z, Feng Q-s, et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014;9:e99857.","journal-title":"PLoS One"},{"key":"3003_CR4","first-page":"986","volume":"45","author":"ZF Zhao","year":"2024","unstructured":"Zhao ZF, Liu ZJ, Wang Y, Sun YQ, Xu LP, Zhang XH, et al. Analysis of CMV and EBV infection in healthy populations in China before and after the COVID-19 pandemic. Zhonghua Xue Ye Xue Za Zhi. 2024;45:986\u201390.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"3003_CR5","doi-asserted-by":"publisher","first-page":"53.e1","DOI":"10.1016\/j.jtct.2021.09.021","volume":"28","author":"M Kinzel","year":"2022","unstructured":"Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, et al. Risk factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:53.e1\u2013.e10.","journal-title":"Transplant Cell Ther"},{"key":"3003_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803.","journal-title":"Haematologica"},{"key":"3003_CR7","doi-asserted-by":"crossref","unstructured":"Law N, Logan C, Taplitz R. EBV Reactivation and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients and its impact on HSCT outcomes. Viruses. 2024;14:1294.","DOI":"10.3390\/v16081294"},{"key":"3003_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41409-023-02129-7","volume":"59","author":"J Styczynski","year":"2024","unstructured":"Styczynski J, Tridello G, Wendel L, Knelange N, Cesaro S, Gil L, et al. Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT. Bone Marrow Transplant. 2024;59:59\u201365.","journal-title":"Bone Marrow Transplant"},{"key":"3003_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2007.06.020","volume":"40","author":"P Comoli","year":"2008","unstructured":"Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein\u2013Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells, Molecules, Dis. 2008;40:68\u201370.","journal-title":"Blood Cells, Molecules, Dis"},{"key":"3003_CR10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/bmt.2009.302","volume":"45","author":"M Faraci","year":"2010","unstructured":"Faraci M, Caviglia I, Morreale G, Lanino E, Cuzzubbo D, Giardino S, et al. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transplant. 2010;45:1052\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"3003_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"J Styczynski","year":"2013","unstructured":"Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794\u2013802.","journal-title":"Clin Infect Dis"},{"key":"3003_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1080\/10428194.2017.1365860","volume":"59","author":"A Kinch","year":"2018","unstructured":"Kinch A, Hallb\u00f6\u00f6k H, Arvidson J, S\u00e4llstr\u00f6m K, Bondeson K, Pauksens K. Long-term outcome of Epstein\u2013Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. Leuk Lymphoma. 2018;59:1172\u20139.","journal-title":"Leuk Lymphoma"},{"key":"3003_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5045\/br.2018.53.2.145","volume":"53","author":"B-K Park","year":"2018","unstructured":"Park B-K, Kim H-S, Kim S, Lee J-W, Park YS, Jang P-S, et al. Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin. Blood Res. 2018;53:145\u201351.","journal-title":"Blood Res"},{"key":"3003_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13574","volume":"23","author":"S Althubaiti","year":"2019","unstructured":"Althubaiti S, Ali S, Renzi S, Krueger J, Chiang KY, Schechter T, et al. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor. Pediatr Transpl. 2019;23:e13574.","journal-title":"Pediatr Transpl"},{"key":"3003_CR15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","volume":"98","author":"X-N Gao","year":"2019","unstructured":"Gao X-N, Lin J, Wang L-J, Li F, Li H-H, Wang S-H, et al. Risk factors and clinical outcomes of Epstein\u2013Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Ann Hematol. 2019;98:2163\u201377.","journal-title":"Ann Hematol"},{"key":"3003_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903063","volume":"13","author":"SP Kania","year":"2022","unstructured":"Kania SP, Silva JMF, Charles OJ, Booth J, Cheung SYA, Yates JWT, et al. Epstein-Barr virus reactivation after paediatric haematopoietic stem cell transplantation: risk factors and sensitivity analysis of mathematical model. Front Immunol. 2022;13:903063.","journal-title":"Front Immunol"},{"key":"3003_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492367","volume":"15","author":"G Ferrando","year":"2024","unstructured":"Ferrando G, Bagnasco F, Pierri F, Pestarino S, Dell\u2019Orso G, Giardino S, et al. Epstein-Barr virus reactivation in pediatric allogeneic stem cell transplant recipients: an 11-year experience on viral load and B lymphocyte monitoring strategy. Front Immunol. 2024;15:1492367.","journal-title":"Front Immunol"},{"key":"3003_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1627990","volume":"13","author":"L Jia","year":"2025","unstructured":"Jia L, Yang H, Zhou Y, Meng Y, Zhang L, Lei X, et al. Analysis of risk factors for Epstein-Barr virus reactivation and progression to post-transplant lymphoproliferative disorder in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. Front Pediatr. 2025;13:1627990.","journal-title":"Front Pediatr"},{"key":"3003_CR19","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","volume":"21","author":"LP Xu","year":"2015","unstructured":"Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transpl. 2015;21:2185\u201391.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3003_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14052","volume":"25","author":"PR Enok Bonong","year":"2021","unstructured":"Enok Bonong PR, Buteau C, Duval M, Lacroix J, Laporte L, Tucci M, et al. Risk factors for post-transplant Epstein-Barr virus events in pediatric recipients of hematopoietic stem cell transplants. Pediatr Transpl. 2021;25:e14052.","journal-title":"Pediatr Transpl"},{"key":"3003_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3324\/haematol.2024.286265","volume":"110","author":"XY Pei","year":"2025","unstructured":"Pei XY, Huang Q, Luo LJ, Sun HL, Liu J, Sun YQ, et al. Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation. Haematologica. 2025;110:1005\u20139.","journal-title":"Haematologica"},{"key":"3003_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","volume":"25","author":"A Fujimoto","year":"2019","unstructured":"Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, et al. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:1441\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3003_CR23","doi-asserted-by":"publisher","unstructured":"Styczynski J, Giebel S. Posttransplant lymphoproliferative syndromes. The EBMT Handbook: Hematopoietic Cell Transplantation and CellularTherapies (eds Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E) 2024;411-8.. Springer International Publishing\/Springer Nature Switzerland AG. https:\/\/doi.org\/10.1007\/978-3-031-44080-9_45","DOI":"10.1007\/978-3-031-44080-9_45"},{"key":"3003_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","volume":"99","author":"M Uhlin","year":"2014","unstructured":"Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99:346\u201352.","journal-title":"Haematologica"},{"key":"3003_CR25","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1182\/blood-2025-4280","volume":"146","author":"F Gao","year":"2025","unstructured":"Gao F, Wang X, Luo Y, Yu J, Fu H, Lai X, et al. Incidence and risk factors of Epstein\u2013Barr virus reactivation and post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a 985-patient retrospective cohort analysis. Blood. 2025;146:4280.","journal-title":"Blood"},{"key":"3003_CR26","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"3003_CR27","doi-asserted-by":"publisher","first-page":"e0042025","DOI":"10.1128\/aac.00420-25","volume":"69","author":"AH Groll","year":"2025","unstructured":"Groll AH, Danziger-Isakov L, Gefen A, Fraser CJ, Schulte JH, Bielorai B, et al. Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study. Antimicrob Agents Chemother. 2025;69:e0042025.","journal-title":"Antimicrob Agents Chemother"},{"key":"3003_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","volume":"59","author":"F Galaverna","year":"2024","unstructured":"Galaverna F, Baccelli F, Zama D, Tridello G, Masetti R, Soncini E, et al. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP). Bone Marrow Transpl. 2024;59:505\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"3003_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-025-00665-0","volume":"14","author":"J Huang","year":"2025","unstructured":"Huang J, Zhou J, Zhang S, Zhang R, Pan Z, Wang L, et al. Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis. Exp Hematol Oncol. 2025;14:72.","journal-title":"Exp Hematol Oncol"},{"key":"3003_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood-2024-202762","volume":"144","author":"J Huang","year":"2024","unstructured":"Huang J, Zhou J, Zhang S, Zhang R, Pan Z, Wang L, et al. Epstein-Barr virus reactivation and post-transplant lymphoproliferative disorders after Allo-HSCT in the era of letermovir for cytomegalovirus prophylaxis. Blood. 2024;144:268.","journal-title":"Blood"},{"key":"3003_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:642\u20139.","journal-title":"Transplant Cell Ther"},{"key":"3003_CR32","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","volume":"2","author":"JE Levine","year":"2015","unstructured":"Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21\u2013e9.","journal-title":"Lancet Haematol"},{"key":"3003_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2025.101634","volume":"38","author":"W Fu","year":"2025","unstructured":"Fu W, Chen J, Hu X. Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions. Best Pr Res Clin Haematol. 2025;38:101634.","journal-title":"Best Pr Res Clin Haematol"},{"key":"3003_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70206","volume":"6","author":"XD Ma","year":"2025","unstructured":"Ma XD, Xu ZL, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation with different non-T-cell depletion protocols. MedComm. 2025;6:e70206.","journal-title":"MedComm"},{"key":"3003_CR35","doi-asserted-by":"crossref","unstructured":"Sharma S. K. Basics of hematopoietic stem cell transplant: Singapore; Springer; 2023.","DOI":"10.1007\/978-981-19-5802-1"},{"key":"3003_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1140637","volume":"11","author":"C Moreno","year":"2023","unstructured":"Moreno C, Ramos-Elbal E, Velasco P, Aguilar Y, Gonz\u00e1lez Mart\u00ednez B, Fuentes C, et al. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: a collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON\/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Front Pediatric. 2023;11:1140637.","journal-title":"Front Pediatric"},{"key":"3003_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1639463","volume":"15","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang S, Fan Z, Huang F, Xu N, Jin H, et al. Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis. Front Cell Infect Microbiol. 2025;15:1639463.","journal-title":"Front Cell Infect Microbiol"},{"key":"3003_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/CM9.0000000000003443","volume":"138","author":"X Pei","year":"2025","unstructured":"Pei X, Lv M, Mo X, Sun Y, Chen Y, Yan C, et al. Long-term efficacy of CMV\/EBV virus-specific T cells for viral co-reactivation after stem cell transplantation. Chin Med J. 2025;138:607\u20139.","journal-title":"Chin Med J"},{"key":"3003_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/509296","volume":"2012","author":"SK Ghosh","year":"2012","unstructured":"Ghosh SK, Perrine SP, Faller DV. Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies. Adv Virol. 2012;2012:509296.","journal-title":"Adv Virol"},{"key":"3003_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720937150","volume":"11","author":"TL Shigle","year":"2020","unstructured":"Shigle TL, Handy VW, Chemaly RF. Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. Ther Adv Hematol. 2020;11:2040620720937150.","journal-title":"Ther Adv Hematol"},{"key":"3003_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/(SICI)1096-9071(199811)56:3<186::AID-JMV2>3.0.CO;2-3","volume":"56","author":"SM Aalto","year":"1998","unstructured":"Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol. 1998;56:186\u201391.","journal-title":"J Med Virol"},{"key":"3003_CR42","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1111\/ctr.12172","volume":"27","author":"F Zallio","year":"2013","unstructured":"Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, et al. E pstein\u2013B arr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant. 2013;27:E491\u2013E7.","journal-title":"Clin Transplant"},{"key":"3003_CR43","first-page":"S518","volume":"31","author":"T Shafat","year":"2025","unstructured":"Shafat T, Khawaja F, Daher M, Jiang Y, Chemaly RF. The interplay between EBV and CMV reactivations following allogeneic hematopoietic cell transplantation in the era of primary CMV prophylaxis. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2025;31:S518.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"3003_CR44","unstructured":"Gupta M, Shorman M. Cytomegalovirus Infections. StatPearls: StatPearls Publishing; USA; Treasure Island (FL); 2025."},{"key":"3003_CR45","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/pathogens14100998","volume":"14","author":"X Liu","year":"2025","unstructured":"Liu X, Liu C, Zhang T. The immunoregulatory mechanisms of human cytomegalovirus from primary infection to reactivation. Pathogens. 2025;14:998.","journal-title":"Pathogens"},{"key":"3003_CR46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/curroncol28010089","volume":"28","author":"M Sabloff","year":"2021","unstructured":"Sabloff M, Tisseverasinghe S, Babadagli ME, Samant R. Total body irradiation for hematopoietic stem cell transplantation: what can we agree on? Curr Oncol. 2021;28:903\u201317.","journal-title":"Curr Oncol"},{"key":"3003_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.virol.2005.12.030","volume":"348","author":"JM Grayson","year":"2006","unstructured":"Grayson JM, Laniewski NG, Holbrook BC. Partial reconstitution of virus-specific memory CD8+ T cells following whole body \u03b3-irradiation. Virology. 2006;348:47\u201356.","journal-title":"Virology"},{"key":"3003_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41409-023-02127-9","volume":"59","author":"G Soci\u00e9","year":"2024","unstructured":"Soci\u00e9 G, Barba P, Barlev A, Sanz J, Garc\u00eda-Cadenas I, Chevallier P, et al. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. Bone Marrow Transpl. 2024;59:52\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3003_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925\u201335.","journal-title":"Blood"},{"key":"3003_CR50","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644\u201356.","journal-title":"Blood"},{"key":"3003_CR51","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733\u201347.","journal-title":"J Clin Invest"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03003-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:03:15Z","timestamp":1793984595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03003-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3003"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03003-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all individual participants (or their legal guardians) prior to inclusion in the study, including specific consent for the use of biological specimens.","order":2,"name":"Ethics","label":"Informed consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}